GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DarioHealth Corp (NAS:DRIO) » Definitions » Change In Receivables

DarioHealth (DarioHealth) Change In Receivables : $2.84 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is DarioHealth Change In Receivables?

DarioHealth's change in receivables for the quarter that ended in Dec. 2023 was $1.28 Mil. It means DarioHealth's Accounts Receivable declined by $1.28 Mil from Sep. 2023 to Dec. 2023 .

DarioHealth's change in receivables for the fiscal year that ended in Dec. 2023 was $2.84 Mil. It means DarioHealth's Accounts Receivable declined by $2.84 Mil from Dec. 2022 to Dec. 2023 .

DarioHealth's Accounts Receivable for the quarter that ended in Dec. 2023 was $3.16 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. DarioHealth's Days Sales Outstanding for the three months ended in Dec. 2023 was 79.62.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. DarioHealth's liquidation value for the three months ended in Dec. 2023 was $3.45 Mil.


DarioHealth Change In Receivables Historical Data

The historical data trend for DarioHealth's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DarioHealth Change In Receivables Chart

DarioHealth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.38 -0.60 -0.37 -5.11 2.84

DarioHealth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.03 2.73 -1.61 0.44 1.28

DarioHealth Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DarioHealth  (NAS:DRIO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

DarioHealth's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=3.155/3.616*91
=79.62

2. In Ben Graham's calculation of liquidation value, DarioHealth's accounts receivable are only considered to be worth 75% of book value:

DarioHealth's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=36.797-38.245+0.75 * 3.155+0.5 * 5.062
=3.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DarioHealth Change In Receivables Related Terms

Thank you for viewing the detailed overview of DarioHealth's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


DarioHealth (DarioHealth) Business Description

Traded in Other Exchanges
N/A
Address
18 W. 18th Street, New York, NY, USA, 10011
DarioHealth Corp is a digital health company. It offers user-centric a multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally.
Executives
Jon H. Kaplan director 1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Erez Raphael director, officer: Chief Executive Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Dror Bacher officer: Chief Operating Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK L3 3088900
Oded Cohen officer: GM MSK 8 HATOKHEN ST., CAESAREA INDUSTRIAL PARK L3 3088900
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Dennis Matheis director 8 HATOKHEN ST., CAESAREA L3 38900
Yoav Shaked director 8 HATOKHEN ST., CAESAREA L3 3088900
Yadin Shemmer director 8 HATOKHEN ST., CAESAREA L3 3088900
Richard Allan Anderson officer: President, GM of North America C/O DARIOHEALTH CORP., 18 W. 18TH ST, 5TH FLOOR, NEW YORK NY 10011
Yalon Farhi director C/O LABSTYLE INNOVATIONS CORP., 9 HALAMISH ST., CAESAREA INDUSTRIAL PARK, CAESAREA L3 3088900
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Zvi Ben-david officer: Chief Financial Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Glen Moller director 8 HATOKHEN ST., CAESAREA L3 3088900
Olivier Roger Jarry officer: See Remarks 15 ROCKRIDGE RD, LARCHMONT NY 10538-3918